文献速递肿瘤 PET/CT

18F-FDG PET/CT预测食管癌新辅助放化疗后残留病的准确性

Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
PubMed 文献 · J Nucl Med · 2019-03-15

本研究前瞻性评估食管癌患者新辅助放化疗后12–14周18F-FDG PET/CT定性和定量分析对残留病的预测价值。定性分析在15%患者中未能检出TRG3-4,定量参数在27%–61%患者中未能检出TRG3-4;但PET/CT在10%患者中检出间期转移。结论认为PET/CT不能准确检测TRG3-4或区分明显残留病与良性炎症性摄取,但可用于检出间期转移。

要点

  • 定性PET/CT在15%患者中未能检出TRG3-4残留病。
  • 定量参数在27%–61%患者中未能检出TRG3-4。
  • PET/CT在10%随访患者中检出新发间期转移。

核心结论

  • 18F-FDG PET/CT定性和定量分析均不能准确检测TRG3-4残留病,也不能区分明显残留病与良性炎症性摄取。
  • 18F-FDG PET/CT有助于检出间期转移,可能适用于系列PET/CT主动监测策略。

研究设计与样本

  • 本研究为前瞻性诊断性pre-SANO试验的侧研究,共分析219例中的129例食管癌患者。
  • 在新辅助放化疗前和放化疗后12–14周行18F-FDG PET/CT,定性评估肿瘤存在,并测量SULmax。
  • 主要终点为定性和定量分析中TRG3-4(>10%存活残留肿瘤)患者的假阴性比例。

主要发现

  • 定性分析检测TRG1 vs TRG2-4的敏感性、特异性、阴性预测值和阳性预测值分别为80%、37%、42%和77%。
  • 定量参数在27%–61%患者中未能检测TRG3-4。
  • 190例中有18例(10%)在随访扫描中检出新发间期转移。

关键数值与推荐

  • 检测TRG1 vs TRG2-4的最佳cutoff为放化疗后SULmax 2.93(AUC 0.70)。

临床怎么用

  • 不应单独依赖18F-FDG PET/CT定性和定量分析来判断新辅助放化疗后是否存在TRG3-4残留病。
  • 可利用18F-FDG PET/CT检出间期转移,并考虑在主动监测策略中系列扫描。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our purpose was to prospectively investigate optimal evaluation of qualitative and quantitative 18F-FDG PET/CT in response evaluations 12-14 wk after neoadjuvant chemoradiotherapy (nCRT) in esophageal cancer patients. Methods: This was a side study of the prospective diagnostic pre-SANO trial. 18F-FDG PET/CT scans at baseline and at 12-14 wk after nCRT were qualitatively assessed for the presence of tumor. Maximum SUVs normalized for lean body mass (SULmax) were measured in all scans. The primary endpoint was the proportion of false-negative patients with tumor regression grade (TRG) 3-4 (>10% vital residual tumor) in qualitative and quantitative analyses. Receiver-operating-characteristic curve analysis for TRG1 versus TRG3-4 using SULmax, SULmax tumor-to-esophagus ratio, and Δ%SULmax was performed to define optimal cutoffs. Secondary endpoints were sensitivity, specificity, negative predictive value, and positive predictive value for TRG1 versus TRG2-4. Results: In total, 129 of 219 patients were analyzed. Qualitative 18F-FDG PET/CT was unable to detect TRG3-4 in 15% of patients. Sensitivity, specificity, negative predictive value, and positive predictive value in qualitative analysis for detecting TRG1 versus TRG2-4 was 80%, 37%, 42%, and 77%, respectively. In 18 of 190 patients (10%) with follow-up scans after nCRT, 18F-FDG PET/CT identified new interval metastases. Quantitative parameters did not detect TRG3-4 tumor in 27%-61% of patients. The optimal cutoff for detecting TRG1 versus TRG2-4 was a post-nCRT SULmax of 2.93 (area under receiver-operating-characteristic curve, 0.70). Conclusion: Qualitative and quantitative analyses of 18F-FDG PET/CT are unable to accurately detect TRG3-4 and to discriminate substantial residual disease from benign inflammation-induced 18F-FDG uptake after nCRT. However, 18F-FDG PET/CT is useful for the detection of interval metastases and might become useful in an active surveillance strategy with serial 18F-FDG PET/CT scanning.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Valkema MJ, Noordman BJ, Wijnhoven BPL, et al. Accuracy of 18F-FDG PET/CT in Predicting Residual Disease After Neoadjuvant Chemoradiotherapy for Esophageal Cancer. J Nucl Med. 2019. PMID: 30877177. doi:10.2967/jnumed.118.224196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。